124 results
Page 3 of 7
8-K
EX-99.1
ivqvdeb7cko5s
4 Nov 19
Karyopharm Reports Third Quarter 2019 Financial Results and Highlights Recent Company Progress
7:07am
8-K
EX-99.1
fd1v qczqp8
16 Sep 19
Entry into a Material Definitive Agreement
7:09am
8-K
EX-99.1
p66bkcze45nb5y al
6 Aug 19
Results of Operations and Financial Condition
7:13am
8-K
EX-99.1
1i6i09 v3o6m4i
3 Jul 19
Karyopharm Announces FDA Approval of XPOVIOTM(selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
1:10pm
8-K
EX-99.1
lzau0d4uzvtzrvck3si
19 Jun 19
Karyopharm Reports Updated Data from the Phase 2b SADAL Study at the 2019 International Conference on Malignant Lymphoma
4:05pm
8-K
EX-99.1
ac41ak 5s7ej7f4ucke
14 Jun 19
Other Events
7:33am
424B5
jrcgb0xo
10 May 19
Prospectus supplement for primary offering
4:16pm
8-K
EX-99.1
b9ihygqajx88 w2yq
9 May 19
Results of Operations and Financial Condition
7:10am
PRE 14A
o1rpvvp
2 Apr 19
Preliminary proxy
4:29pm
8-K
EX-99.1
x8mf80q3dx
15 Mar 19
Karyopharm Announces FDA Extension of Review Period for Selinexor New Drug Application
7:00am
POS AM
2ly r8tgw1g7xaapm
28 Feb 19
Prospectus update (post-effective amendment)
4:54pm
POSASR
yfcwrh00i34ncc1m05m
28 Feb 19
Automatic shelf registration (post-effective amendment)
4:17pm
8-K
EX-99.1
mw8tvc03k7cile
28 Feb 19
Karyopharm Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
7:22am
8-K
EX-10.1
xvx47
25 Feb 19
Departure of Directors or Certain Officers
5:01pm